Open Trials- February 2020

Breast Cancer Trials:

A study of xentuzumab + everolimus and exemestane VS everolimus and exemestane in post-menopausal women with HR+ / HER2 – metastatic breast cancer and non-visceral disease (Xenera 1)

A study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate, VS Treatment of Investigator’s Choice for HER2 +, Unresectable and/or Metastatic Breast Cancer in Subjects Pretreated with Prior Standard of Care therapies including T-DM1 (DESTINY-Breast 02)

A Study of DS8201a, an Anti-HER2-Antibody Drug Conjugate (ADC), versus Treatment of Investigator’s Choice for HER2-low Unresectable and/or Metastatic Breast Cancer.

(DESTINY-Breast 04)

A Prospective Registry study to Evaluate the Effect of the DCISionRT test on Treatment Decisions in Patient with DCIS Following Breast Conserving Therapy

(Available Late December 2020)

For questions regarding this study, please contact 480-398-7671

Lung Cancer Trials:

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

A Study of Pembrolizumab (Keytruda) + Lenvatinib or placebo for treatment Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC) with TPS ≥ 1% (LEAP 007)

For questions regarding this study, please contact 480-398-7671

Melanoma Trials:

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

Enrollment on this trial is on hold. Please contact Ironwood Cancer & Research Centers for status update

For questions, please contact 480-398-7671

Prostate Trials:

A Study of Talazoparib + Enzalutamide vs Enzalutamide in Metastatic Castration-Resistant

Prostate Cancer


Lymphoma Studies:

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin’s Lymphoma (UNITY-NHL)

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4)

For questions regarding this study, please contact 480-398-7671

Solid Tumor Trials:

A Study of Selective Pan-FGFR inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a

Fusion of FGFR1, FGFR2, or FGFR3 (FUZE)